RT Journal Article
SR Electronic
T1 Establishment of a Mouse Gastrointestinal Stromal Tumour Model and Evaluation of Response to Imatinib by Small Animal Positron Emission Tomography
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1247
OP 1252
VO 26
IS 2A
A1 PRENEN, HANS
A1 DEROOSE, CHRISTOPHE
A1 VERMAELEN, PETER
A1 SCIOT, RAF
A1 DEBIEC-RYCHTER, MARIA
A1 STROOBANTS, SIGRID
A1 MORTELMANS, LUC
A1 SCHÖFFSKI, PATRICK
A1 VAN OOSTEROM, ALLAN
YR 2006
UL http://ar.iiarjournals.org/content/26/2A/1247.abstract
AB Background: Gastrointestinal stromal tumours (GIST) predominantly express activating mutations of the KIT tyrosine kinase receptor and are successfully treated with imatinib mesylate, a KIT inhibitor. As resistance to imatinib causes therapy failure, our aim was to develop an in vivo GIST model to evaluate KIT inhibitors and monitor therapy with small animal positron emission tomography (PET). Materials and Methods: The first mouse model of GIST xenografts was successfully established by injecting GIST882 cells subcutaneously into nude mice. Results: Using the small animal PET, FDG up-take in xenografts was significantly decreased after 24 h of treatment with imatinib, which correlated with a response to treatment, e.g., with a decrease in tumour volume, the inhibition of KIT and downstream intermediate phosphorylation and arrest of tumour cell proliferation as evaluated after 7 days of treatment. Conclusion: This model is useful to study imatinib resistance and to evaluate novel targeted therapies. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved